RTW Biotech Opportunities Ltd
19 August 2026
LEI: 549300Q7EXQQH6KF7Z84
19 August 2026
RTW Biotech Opportunities Ltd
Appointment of Joint Corporate Broker and Share Repurchase Programme
Appointment of Joint Corporate Broker
RTW Biotech Opportunities Ltd ("RTW Bio" or the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to announce that it has appointed Jefferies International Limited ("Jefferies") with immediate effect as Joint Corporate Broker alongside BofA Securities, who remain Joint Corporate Broker.
Share Repurchase Programme
Jefferies will be appointed as buyback agent of the Company's existing share repurchase programme (the "Programme") with effect from the date of this announcement.
Share purchases may continue during any closed period to which the Company is subject during the duration of the Programme.
The Programme will be conducted in accordance with chapter 9 of the Financial Conduct Authority's Listing Rules. Any purchase of shares under the Programme by Jefferies will be carried out on the London Stock Exchange in accordance with the general authority to purchase shares granted by its shareholders at the Company's latest Annual General Meeting.
Enquiries:
|
RTW Investments, LP - Investment Manager Oliver Kenyon Krisha McCune (Investor Relations) |
+44 (0)20 7959 6362 |
|
Cadarn Capital - PR & IR Partner Lucy Clark (PR) David Harris (Distribution) |
+44 (0)7984 184 461 / lucy@cadarncapital.com +44 (0)7368 883 211 / david@cadarncapital.com |
|
Jefferies International Limited - Joint Corporate Broker Gaudi Le Roux Harry Randall-Knowles |
+44 (0)20 7029 8000 |
|
BofA Securities - Joint Corporate Broker Edward Peel Alex Penney |
+44 (0)20 7628 1000 |
|
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison |
+44 (0)1481 703 100 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwbio.com for more information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.